Yun (Kenneth) Kang

Title: Innovations of Yun (Kenneth) Kang in HIV Research

Introduction

Yun (Kenneth) Kang is a notable inventor based in Livingston, NJ (US). He has made significant contributions to the field of HIV research through his innovative work. His expertise and dedication have led to advancements that may impact the treatment and understanding of HIV.

Latest Patents

Kang holds a patent for "Soluble, stabilized, proteolytically cleaved, trimeric HIV-1 gp140 proteins comprising modifications in the N-terminus of the gp41 ectodomain." This invention provides a modified gp140 envelope polypeptide of an HIV-1 isolate. It includes a gp120 polypeptide portion and a gp41 ectodomain polypeptide portion, with specific modifications at various amino acid positions. The invention also encompasses nucleic acids encoding such polypeptides, vectors, host cells, trimeric complexes, and compositions thereof. Additionally, it provides antibodies generated against the modified polypeptides and methods of using these innovations.

Career Highlights

Kang is currently associated with Progenics Pharmaceuticals, Inc., where he continues to work on groundbreaking research. His contributions to the field have been recognized and valued within the scientific community. He has a patent count of 1 patent, showcasing his innovative capabilities.

Collaborations

Kang has collaborated with notable colleagues, including John S Moore and Michael Franti. These partnerships have likely enhanced the scope and impact of his research endeavors.

Conclusion

Yun (Kenneth) Kang's work in HIV research exemplifies the importance of innovation in addressing global health challenges. His patented inventions and collaborations reflect a commitment to advancing medical science.